Scavenger receptor A in immunity and autoimmune diseases: Compelling evidence for targeted therapy.
Expert Opin Ther Targets
; 26(5): 461-477, 2022 05.
Article
in English
| MEDLINE | ID: covidwho-1956519
ABSTRACT
INTRODUCTION:
Scavenger receptor A (SR-A) is reported to be involved in innate and adaptive immunity and in recent years, the soluble form of SR-A has also been identified. Intriguingly, SR-A displays double-edged sword features in different diseases. Moreover, targeted therapy on SR-A, including genetic modulation, small molecule inhibitor, inhibitory peptides, fucoidan, and blocking antibodies, provides potential strategies for treatment. Currently, therapeutics targeting SR-A are in preclinical studies and clinical trials, revealing great perspectives in future immunotherapy. AREAS COVERED Through searching PubMed (January 1979-March 2022) and clinicaltrials.gov, we review most of the research and clinical trials involving SR-A. This review briefly summarizes recent study advances on SR-A, with particular concern on its role in immunity and autoimmune diseases. EXPERT OPINION Given the emerging evidence of SR-A in immunity, its targeted therapy has been studied in various diseases, especially autoimmune diseases. However, many challenges still remain to be overcome, such as the double-sworded effects and the specific isoform targeting. For further clinical success of SR-A targeted therapy, the crystal structure illustration and the dual function discrimination of SR-A should be further investigated. Nevertheless, although challenging, targeting SR-A would be a potential effective strategy in the treatment of autoimmune diseases and other immune-related diseases.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Autoimmune Diseases
/
Adaptive Immunity
Type of study:
Prognostic study
/
Reviews
Limits:
Humans
Language:
English
Journal:
Expert Opin Ther Targets
Journal subject:
Therapeutics
Year:
2022
Document Type:
Article
Affiliation country:
14728222.2022.2072729
Similar
MEDLINE
...
LILACS
LIS